VIVUS (VVUSQ) Stock Price, News & Analysis

Company Overview

VIVUS, Inc. is a biopharmaceutical company that historically focused on developing and commercializing therapies for obesity, weight management and related health conditions. The company’s operations centered on prescription medicines intended to address significant unmet needs in metabolic and sexual health.

VIVUS is best known for Qsymia, an extended-release combination of phentermine and topiramate approved in the United States for chronic weight management in adults, alongside diet and exercise. The company also developed Stendra, a prescription treatment for erectile dysfunction containing avanafil. Stendra has been marketed under different arrangements and brand names in certain international markets.

Founded in 1991 and headquartered in California, VIVUS underwent financial restructuring, including a Chapter 11 bankruptcy reorganization, in the late 2010s. The company’s commercial activities and ownership structure have changed over time, and the OTC Markets “Q” designation associated with its symbol reflects its bankruptcy-related status. Current operating activities, product rights and leadership information may be limited or subject to change.

Key Stats

• Today's Range: $0.12 to $0.12
• 50-Day Range: $0.12 to $0.12
• 52-Week Range: $0.07 to $4.55
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:VVUSQ
• CIK: N/A
• Web: www.vivus.com
• Phone: 650-934-5200
• Fax: 650-934-5389
• Employees: 57
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A